VITRUVIAE is a preclinical biotechnology company developing immunotherapies targeting Man 9 (a sugar) and PS (a lipid) to treat cancer. Their lead therapy, VIT-GLT3, is a trispecific immunotherapy that targets tumor-specific, non-mutating Man9 and PS, aiming to overcome the limitations of current antitumor treatments.
Investors 2
| Date | Name | Website |
| 30.12.2025 | Casabona V... | casabonave... |
| - | Angel Phys... | angelphysi... |